Good practice and quality assurance in surgical oncology

Lancet Oncology

Volumn 4, Issue 10, 2003, Pages 626-630

  Douek, Michael ^a   Taylor, Irving ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER SURGERY; CHILDHOOD CANCER; COLORECTAL CANCER; ESOPHAGUS CANCER; EXCISION; GOOD CLINICAL PRACTICE; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; METASTASIS; MONITORING; PANCREAS CANCER; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW; SKILL; SOLID TUMOR; STOMACH CANCER; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0141894040     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01222-1     Document Type: Review

References (45)

1. Taylor I. What constitutes good practice in surgical oncology? Eur J Surg Oncol 200; 27: 517-20.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-46.
3. Martling A, Holm T, Johansson H, et al. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 2001; 92: 896-902.
4. Olsen O, Gotzsche PC. Screening for breast cancer with mammography (Cochrane Review). Cochrane Database Syst Rev 2001; 4: CD001877.
5. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-42.
6. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-19.
7. Douek M, Baum M. Mass breast screening: is there a hidden cost? Br J Surg 2003; 90: 44-45.
8. Nattinger AB, Hoffman RG, Shapiro R, et al. The effect of legislative requirements on the use of breast-conserving surgery. N Engl J Med 1996; 335: 1035-40.
9. Hospital Episode Statistics, Department of Health, UK. 21-10-2002. http://www.doh.gov.uk/hes/, accessed September 2003.
10. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-62.
11. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-55.
12. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1757-70.
13. Nattinger AB, Hoffmann RG, Kneusel RT, Schapira MM. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet 2000; 356: 1148-53.
14. Clarke D, Khonji NI, Mansel RE. Sentinel node biopsy in breast cancer: ALMANAC trial. World J Surg 2001; 25: 819-22.
15. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 2001; 20: 230-37.
16. Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994; 344: 707-11.
17. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-82.
18. Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000; 356: 93-96.
19. National Institute for Clinical Exellence, London, UK. 30-8-2002. http://www.nice.org.uk/, accessed September 2003.
20. McArdle CS, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 1991; 302: 1501-05.
21. Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. Improving the quality of cancer services. London: UK Department of Health, 1995: 1-37
22. Landheer M, Therasse P, van de Velde CJ. The importance of quality assurance in surgical oncology. Eur J Surg Oncol 2002; 28: 571.
23. Chaudhry R, Goel V, Sawka C. Breast cancer survival by teaching status of the initial treating hospital. CMAJ 2001; 164: 183-88.
24. Karjalainen S. Geographical variation in cancer patient survival in Finland: chance, confounding, or effect of treatment? J Epidemiol Community Health 1990; 44: 210-14.
25. Sainsbury R, Rider L, Smith A, MacAdam A. Does it matter where you live? Treatment variation for breast cancer in Yorkshire. The Yorkshire Breast Cancer Group. Br J Cancer 1995; 71: 1275-78.
26. McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 2002; 86: 331-35.
27. Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland. BMJ 1996; 312: 145-48.
28. Kingston RD, Walsh S, Jeacock J. Colorectal surgeons in district general hospitals produce similar survival outcomes to their teaching hospital colleagues: review of 5-year survivals in Manchester. J R Coll Surg Edin 1992; 37: 235-37.
29. Sainsbury R, Haward B, Rider L, et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995; 345: 1265-70.
30. Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeon-related factors and outcome in rectal cancer. Ann Surg 1998; 227: 157-67.
31. Parry JM, Collins S, Mathers J, et al. Influence of volume of work on the outcome of treatment for patients with colorectal cancer. Br J Surg 1999; 86: 475-81.
32. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989; 299: 1069-72.
33. Davis S, Dahlberg S, Myers MH, et al. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst 1987; 78: 471-78.
34. Gillis CR, Hole DJ, Still RM, et al. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 1991; 337: 611-12.
35. Iunor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994; 70: 363-70.
36. Matthews HR, Powell DJ, McConkey CC. Effect of surgical experience on the results of resection for oesophageal carcinoma. Br J Surg 1986; 73: 621-23.
37. Edge SB, Schmieg RE Jr, Rosenlof LK, Wilhelm MC. Pancreas cancer resection outcome in American University centers in 1989-1990. Cancer 1993; 71: 3502-08.
38. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991; 9: 818-26.
39. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 1993; 341: 999-1002.
40. Stiller CA, Bunch KJ. Trends in survival for childhood cancer in Britain diagnosed 1971-85. Br J Cancer 1990; 62: 806-15.
41. Stiller CA, Draper GJ. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child 1989; 64: 657-61.
42. Vantongelen K, Steward W, Blackledge G, et al. EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials. Eur J Cancer 1991; 27: 201-07.
43. Steward WP, Vantongeten K, Verweij J, et al. Chemotherapy administration and data collection in an EORTC collaborative group - can we trust the results? Eur J Cancer 1993; 29A: 943-47.
44. Nolan TW. System changes to improve patient safety. BMJ 2000; 320: 771-73.
45. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-62.